Hereditary angioedema
PHVSPharvaris B.V.Catalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for PHVS719 (deucrictibant extended-release tablets) in Hereditary angioedema . The expected timing is based on the latest available company guidance and may change.
CHAPTER-1 OLE, CHAPTER-3 trials. 3/3/25- Presented CHAPTER-1 long-term data at AAAAI/WAO '25. 11/12/25– CHAPTER-3 enrollment progressing; data in H2 2026. 01/12/26:- CHAPTER-3 topline data now expected Q3 2026; CHAPTER-1 final data to be presented at WSAAI/AAAAI 2026. 02/10/26:- CHAPTER-1 final OLE and PK data and CHAPTER-3 ER exposure results at AAAAI 2026. 03/02/26:- Final CHAPTER-1 OLE showed sustained low attacks; ER tablet Ph1 supports once-daily. CHAPTER-3 topline Q3 2026. 04/02/26:- CHAPTER-3 enrollment completed; topline data expected Q3 2026. CHAPTER-4 long-term safety enrollment progressing. 04/20/26:- CIIC 2026 safety margins support XR+IR combo. CHAPTER-3 topline data still expected Q3 2026. 05/29/26:- EAACI June 13 CHAPTER-1 OLE updates; XR+IR safety poster. CHAPTER-3 topline data still expected Q3 2026. 06/15/26:- EAACI 2026 showed CHAPTER-1 OLE final data. CHAPTER-3 topline still expected Q3 2026. 08/12/26:- CHAPTER-3 topline data remains expected in Q3 2026. CHAPTER-1 Phase 2 results will be presented September 4, 2026.
Verification
Confirm timing and program details against the company announcement or filing.